Clinical data
AHFS/ Monograph
License data
  • US: D (Evidence of risk)
Routes of
ATC code L01BB07 (WHO)
Legal status
Legal status
Pharmacokinetic data
Bioavailability n/a
Protein binding <25%
Metabolism By adenosine deaminase, to 9-β-D-arabinofuranosylguanine
Biological half-life 30 minutes (nelarabine)
3 hours (ara-G)
Excretion Renal
CAS Number 121032-29-9 YesY
PubChem (CID) 3011155
DrugBank DB01280 YesY
ChemSpider 2280207 YesY
UNII 60158CV180 YesY
KEGG D05134 N
ECHA InfoCard 100.170.768
Chemical and physical data
Formula C11H15N5O5
Molar mass 297.268 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. It was previously known as 506U78.

Nelarabine is arabinosylguanine nucleotide triphosphate (araGTP), a type of purine nucleoside analog, which causes inhibition of DNA synthesis and cytotoxicity.[1] Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In October 2005, it was approved by the FDA for acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least two chemotherapy regimens.[2] It was later approved in the European Union in October 2005. Complete responses have been achieved with this medication.

It is marketed in the US as Arranon and as Atriance in the EU by Novartis.[3]


  1. "Nelarabine". Guide to Pharmacology. IUPHAR/BPS. Retrieved 21 August 2015.
  2. Cohen, M. H.; Johnson, J. R.; Justice, R; Pazdur, R (2008). "FDA drug approval summary: Nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma". The Oncologist. 13 (6): 709–14. doi:10.1634/theoncologist.2006-0017. PMID 18586926.

This article is issued from Wikipedia - version of the 11/21/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.